Company / Gross Profit per Share
ELITE PHARMACEUTICALS INC /NV/ Gross Profit per Share History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit per Share
$0.04
FY2024
5-year range
$0.02 / $0.04
FY2020-FY2024
Trend
+51.7%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Gross Profit per Share has fluctuated over the past 9 years, ranging from $0.00 in FY2018 to $0.04 in FY2024.
Based on SEC 10-K filings.
0.04 in FY2024 with a 5-year CAGR of +31.8%.
Improved from $0.02 to $0.04 over the past 2 years.
Gross Profit per Share over time
Growth rates
- 3-Year CAGR
- +31.0%
- 5-Year CAGR
- +31.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, gross profit per share increased 51.7% year-over-year.
- Lowest gross profit per share in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.19 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross Profit per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $0.04 | +51.7% |
| FY2023 | $0.03 | +58.5% |
| FY2022 | $0.02 | -6.6% |
| FY2021 | $0.02 | +22.4% |
| FY2020 | $0.01 | +44.7% |
| FY2019 | $0.01 | +221.7% |
| FY2018 | $0.00 | -44.3% |
| FY2017 | $0.01 | -6.4% |
| FY2016 | $0.01 | -58.6% |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026